Đánh giá kết quả hóa trị triệu chứng bước 1 ở bệnh nhân ung thư dạ dày giai đoạn tiến xa bằng phác đồ có epirubicin, oxaliplatin, capecitabin

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thanh Phuc Nguyen, Thi Dieu Đao Nguyen, Thi Hong Chuyen Nguyen, Tran Thuc Huan Nguyen, Van Cau Nguyen, Phuong Phung

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Journal of Clinical Medicine – Hue Central Hospital, 2020

Mô tả vật lý: tr.102-109

Bộ sưu tập: Metadata

ID: 379310

Thêm vào giỏ Liên kết toàn văn

Mục đích: Khảo sát đặc điểm lâm sàng và cận lâm sàng ở bệnh nhân ung thư dạ dày giai đoạn tiến xa. Đánh giá thời gian sống còn toàn bộ và thời gian sống bệnh không tiến triển, tỷ lệ đáp ứng và độc tính hóa trị trên bệnh nhân ung thư dạ dày giai đoạn tiến xa bằng hóa trị triệu chứng bước 1 với phác đồ có epirubicin, oxaliplatin, capecitabin. Phương pháp: Nghiên cứu mô tả loạt ca hồi cứu cứu trên 134 bệnh nhân ung thư dạ dày giai đoạn tiến xa được hóa trị bằng phác đồ có epirubicin, oxaliplatin, capecitabin tại bệnh viện Đại học Y Dược Huế và Trung tâm Ung bướu bệnh viện Trung ương Huế từ tháng 1/2015 đến tháng 6/2019. Kết quả: Tuổi trung bình 54,9 tuổi, tỷ lệ nam/nữ là 2,52/1. Triệu chứng lâm sàng thường gặp nhất là đau bụng thượng vị (81,3%). Phần lớn bệnh nhân có chỉ số toàn trạng KPS trước điều trị từ 80- 90% (93,3%). Hang môn vị là vị trí tổn thương thường gặp nhất (61,9%). 58,2% bệnh nhân đã có di căn xa trong đó gan là vị trí gặp nhiều nhất (31,3%). Tỷ lệ đáp ứng toàn bộ, đáp ứng mọt phần, đáp ứng hoàn toàn lần lượt là 49,2%
42,5%
6,7%. Thể mô bệnh học và phẫu thuật phối hợp trước hóa trị là các yếu tố liên quan đến đáp ứng . Trung vị thời gian sống thêm bệnh không tiến triển là 8,6 ± 0,15 tháng. Trung vị thời gian sống thêm bệnh toàn bộ là 10,7 ± 1,1 tháng. Độc tính do thuốc độ 3 và 4 về huyết học, chức năng gan thận và một số tác dụng không mong muốn trên lâm sàng ở mức độ thấp, bệnh nhân dung nạp được thuốc, không có trường hợp tử vong do hóa trị Kết luận: Nghiên cứu cho thấy phác đồ EOX thể hiện tính an toàn và hiệu quả. Vì vậy có thể sử dụng điều trị triệu chứng cho những bệnh nhân UTDD giai đoạn tiến xa có có trạng thái hoạt động cơ thể KPS ≥70%.Purpose:to study clinical and subclinical characteristics in advanced stage gastric cancer patients andto evaluate response rate, overall survival, progression free survival and toxicities on advanced stage gastric cancer patients treated with first line chemotherapy using epirubicin, oxaliplatin, capecitabinMethods: A retrospective case series study with 134 advanced stage gastric cancer patients on first linechemotherapy using epirubicin, oxaliplatin, capecitabin recruited from oncology department, the Hospitalof Hue University of Medicine and Pharmacy and Cancer Center at Hue Central Hospital during January2015 to June 2019.Results: Patient’s mean age was 54,9
men/women was 2,52/1. The most frequent clinical symptomreported was epigastric pain 81,3%. KPS 80-90% presented in almost patient (93.3%). The most commonsite of cancer was pyloric antrum (61,9%). 58,2% patients had distant metastasis disease which liver wasthe most frequent site. The overall response rate, partial response rate, complete response rate were 49,2%,42,5%, 6,7% respectively. The median progression free survival was 8,6 ± 0,15 months and the overallsurvival was 10,7 ± 1,1 months. The pathologic type and combined salvage surgery status were responsecorrelated factors. Grade 3, 4 toxicities in term of hematology, liver and kidney function were only exhibitedin a few cases. Patients were tolerated well with chemotherapy. No deaths related to chemotherapy.Conclusions: This study shows that EOX regimen was safe and effective. As a results, we can applythis for first line pallative chemotherapy on advanced stage gastric cancer which KPS ≥70%.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR